Hap Trading, LLC Aveo Pharmaceuticals, Inc. Call Options Transaction History

Hap Trading, LLC

10 transactions

Quarter	Operation	Price Per call	calls change	calls Held
Q3 2022 Nov 14, 2022	SELL	$6.61 - $8.72 $12,559 - $16,568	-1,900 Reduced 4.66%	38,900 $37,000
Q2 2022 Aug 12, 2022	BUY	$3.51 - $6.67 $72,306 - $137,402	20,600 Added 101.98%	40,800 $28,000
Q1 2022 May 12, 2022	SELL	$3.15 - $6.01 $16,852 - $32,153	-5,350 Reduced 20.94%	20,200 $9,000
Q4 2021 Feb 14, 2022	BUY	$4.69 - $7.4 $16,884 - $26,640	3,600 Added 16.4%	25,550 $0
Q3 2021 Nov 10, 2021	SELL	$5.12 - $6.89 $53,760 - $72,345	-10,500 Reduced 32.36%	21,950 $4,000
Q2 2021 Aug 11, 2021	SELL	$6.21 - $7.45 $31,671 - $37,995	-5,100 Reduced 13.58%	32,450 $23,000
Q1 2021 May 14, 2021	BUY	$5.97 - $15.28 $98,982 - $253,342	16,580 Added 79.07%	37,550 $30,000
Q4 2020 Feb 16, 2021	SELL	$5.08 - $6.68 $27,432 - $36,072	-5,400 Reduced 20.48%	20,970 $12,000
Q3 2020 Nov 13, 2020	BUY	$4.16 - $6.26 $43,097 - $64,853	10,360 Added 64.71%	26,370 $20,000
Q2 2020 Aug 10, 2020	BUY	$3.47 - $9.99 $55,554 - $159,939	16,010 New	16,010 $8,000

Ticker AVEO
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 34,676,000
Description
AVEO Pharmaceuticals, Inc., a biopharmaceutical company, focuses on developing and commercializing medicines for cancer patients. It markets its lead candidate, FOTIVDA, an oral, once-daily, vascular endothelial growth factor receptor tyrosine kinase inhibitor, which is used for the treatment of renal cell carcinoma (RCC); and tivozanib for the ...

Get notified when there are updates to the investment portfolio of Hap Trading, LLC, based on Form 13F filings with the SEC.

Stay updated on Hap Trading, LLC with notifications on news.